BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37499450)

  • 21. A novel interaction of nucleophosmin with BCL2-associated X protein regulating death evasion and drug sensitivity in human hepatoma cells.
    Lo SJ; Fan LC; Tsai YF; Lin KY; Huang HL; Wang TH; Liu H; Chen TC; Huang SF; Chang CJ; Lin YJ; Yung BY; Hsieh SY
    Hepatology; 2013 May; 57(5):1893-905. PubMed ID: 23258611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma.
    Soliman MH; Ragheb MA; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
    Anticancer Agents Med Chem; 2021; 21(2):246-253. PubMed ID: 32416702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
    Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
    Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma.
    Hu TH; Huang CC; Lin PR; Chang HW; Ger LP; Lin YW; Changchien CS; Lee CM; Tai MH
    Cancer; 2003 Apr; 97(8):1929-40. PubMed ID: 12673720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients.
    Lu F; Zhou Q; Liu L; Zeng G; Ci W; Liu W; Zhang G; Zhang Z; Wang P; Zhang A; Gao Y; Yu L; He Q; Chen L
    Theranostics; 2020; 10(2):484-497. PubMed ID: 31903133
    [No Abstract]   [Full Text] [Related]  

  • 26. ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma.
    Yang T; Gao Y; Liu D; Wang Y; Wu J; Liu X; Shi Y; Chen D
    Biochem Biophys Res Commun; 2019 Jan; 508(3):769-774. PubMed ID: 30528232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
    Ma D; Wang J; Liu L; Chen M; Wang Z
    BMC Cancer; 2020 Sep; 20(1):936. PubMed ID: 32993568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.
    Jung EU; Yoon JH; Lee YJ; Lee JH; Kim BH; Yu SJ; Myung SJ; Kim YJ; Lee HS
    Cancer Lett; 2010 Dec; 298(1):9-15. PubMed ID: 20573444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.
    Tang J; Sui CJ; Wang DF; Lu XY; Luo GJ; Zhao Q; Lian QY; Jeong S; Lin XM; Zhu YJ; Zheng B; Wu R; Wang Q; Liu XL; Liu JF; Xia Q; Wu G; Gu J; Wang HY; Chen L
    Theranostics; 2020; 10(12):5384-5397. PubMed ID: 32373219
    [No Abstract]   [Full Text] [Related]  

  • 30. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
    You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
    Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
    Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
    Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The homeobox transcription factor Prox1 inhibits proliferation of hepatocellular carcinoma cells by inducing p53-dependent senescence-like phenotype.
    Chang TM; Hung WC
    Cancer Biol Ther; 2013 Mar; 14(3):222-9. PubMed ID: 23291986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation.
    Ling S; Shan Q; Zhan Q; Ye Q; Liu P; Xu S; He X; Ma J; Xiang J; Jiang G; Wen X; Feng Z; Wu Y; Feng T; Xu L; Chen K; Zhang X; Wei R; Zhang C; Cen B; Xie H; Song P; Liu J; Zheng S; Xu X
    Gut; 2020 Jul; 69(7):1322-1334. PubMed ID: 31776228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma.
    Sgro A; Cursons J; Waryah C; Woodward EA; Foroutan M; Lyu R; Yeoh GCT; Leedman PJ; Blancafort P
    Clin Epigenetics; 2023 Apr; 15(1):73. PubMed ID: 37120619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
    Qin J; Luo M; Qian H; Chen W
    Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
    Sanaei M; Kavoosi F
    Asian Pac J Cancer Prev; 2021 Feb; 22(S1):89-95. PubMed ID: 33576217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Knockdown of the long noncoding RNA PURPL induces apoptosis and sensitizes liver cancer cells to doxorubicin.
    Berhane T; Holm A; Karstensen KT; Petri A; Ilieva MS; Krarup H; Vyberg M; Løvendorf MB; Kauppinen S
    Sci Rep; 2022 Nov; 12(1):19502. PubMed ID: 36376362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
    Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
    Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory factor X5 promotes hepatocellular carcinoma progression by transactivating tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta and suppressing apoptosis.
    Chen DB; Zhao YJ; Wang XY; Liao WJ; Chen P; Deng KJ; Cong X; Fei R; Wu X; Shao QX; Wei L; Xie XW; Chen HS
    Chin Med J (Engl); 2019 Jul; 132(13):1572-1581. PubMed ID: 31188160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation.
    Chou YY; Cheng AL; Hsu HC
    J Gastroenterol Hepatol; 1997 Aug; 12(8):569-75. PubMed ID: 9304508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.